Exelixis logo

Exelixis

EXEL | NASDAQ
Chart Builder DCF Calculator
$67.10
-$1.90 (-2.75%)
At close: Nov 16, 2026, 4:00 PM ET
$65.59
-$1.51 (-2.25%)
After-hours: Nov 16, 2026, 7:58 PM ET
-2.75%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
79.1
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #25/1021 (Top 2%)

Key Statistics

Market Data

Market Cap $16.87B
1D Range
66.87 69.98
52W Range
40.74 72.75

Valuation (TTM)

PE 20.09
PB 9.20
EV/EBITDA 14.98

Valuation (NTM)

Forward PE 23.15
Forward PEG 0.82
Price Target $52.50
Loading financial charts...

Profile

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United St...

Sector Healthcare
Industry Biotechnology
Employees 1,077
IPO Date Apr 17, 2000
Fiscal Year January - December

Latest News

Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything

9 hours ago · fool.com

Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.

3 days ago · fool.com

Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib

5 days ago · marketbeat.com

Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

5 days ago · seekingalpha.com

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears

6 days ago · marketbeat.com

Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

6 days ago · seekingalpha.com

Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Here's Why Exelixis (EXEL) is a Strong Growth Stock

8 days ago · zacks.com

Here's Why Exelixis (EXEL) is a Strong Growth Stock
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations

15 days ago · zacks.com

Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales

18 days ago · zacks.com

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript

18 days ago · seekingalpha.com

Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript

Earnings

Latest Earnings
Oct 29, 2026
EPS
$0.94
Beat +5.98%
REV
$658.7M
Beat +1.88%
Next Earnings
Feb 9, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
12
Consensus
Hold
Price Target
$52.50
Downside
-21.76%
Buy (3)
Hold (9)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.